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MIP-2 or IL-8Annexin A1 (ANXA1) is a well-known anti-inﬂammatory protein that is expressed on the surface of apoptotic
cells. Annexin A4 (ANXA4) is also recruited from the nucleus to the cytoplasm in apoptotic cells, although it is
not known whether or not ANXA4 is expressed on the surface of apoptotic cells. In this study, we obtained
rabbit anti-human ANXA1 and ANXA4 antibodies, and then examined whether or not ANXA1 and ANXA4
are expressed on the surface of early and late human apoptotic cells. ANXA1 and, to a lesser extent, ANXA4
were detected on late but not early apoptotic HeLa cells, whereas ANXA1 and a small amount of ANXA4
were detected on both early and late apoptotic human neutrophils. We then examined the effects of the
anti-human ANXA1 and ANXA4 antibodies on the mouse or human macrophage response to human apopto-
tic cells. Upon coculturing of mouse or human macrophages with late apoptotic human neutrophils, anti-
human ANXA1 antibodies and, to a lesser extent, anti-human ANXA4 antibodies increased MIP-2 or IL-8 pro-
duction signiﬁcantly, suggesting that ANXA1 and ANXA4 suppress MIP-2 or IL-8 production by macrophages
in response to late apoptotic human neutrophils.
© 2011 Elsevier B.V. All rights reserved.1. Introduction
Apoptotic cells are cleared by phagocytes as soon as they appear in
vivo. If phagocytosis is impaired for some reason or if apoptotic cells
outnumber phagocytes, apoptotic cells become late apoptotic or
secondary necrotic ones, and then secrete their intracellular contents,
thereby causing an inﬂammatory response, such as neutrophil inﬁltra-
tion [1]. Consistent with this notion, we previously showed that cocul-
turing of human and mouse macrophages with late apoptotic cells
induced the production of IL-8 and MIP-2, a mouse homolog of IL-8,
one of the chemokines speciﬁc to neutrophils [2,3]. This is also true in
vivo, because whole body X-irradiation induces massive apoptosis in
the thymus, thereby causing MIP-2 production by macrophages and
neutrophil inﬁltration into the thymus [4].
Apoptotic cells express phosphatidylserine (PS) on their surface,
through which phagocytes recognize apoptotic cells [5]. PS is thus the
key molecule for the clearance of apoptotic cells by phagocytes. In sup-
port of this, it has been reported that annexin V inhibits the phagocyto-
sis of apoptotic cells by blocking PS on the apoptotic cells [6].exin A1; ANXA4, annexin A4;
ropidium iodide
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Kobayashi).
l rights reserved.Phagocytes recognize apoptotic cells either directly via a PS receptor
such as TIM-4 [7] or indirectly via bridging molecules such as milk fat
globule epidermal growth factor 8 [8].
Annexin A1 (ANXA1), also called lipocortin, is a member of the
annexin family that binds to PS in a calcium-dependent manner and is
known as an anti-inﬂammatory molecule [9]. Recently, it was reported
that ANXA1 is expressed on the surface of apoptotic cells and assists in
the clearance bymacrophages [10–12]. ANXA1 consists of two domains,
a core domain exhibiting high afﬁnity toward PS and an N terminal one
exhibiting high afﬁnity toward the formyl peptide receptor [13]. It is
thus hypothesized that ANXA1 is best suited for facilitating phagocyto-
sis because of these two domains. However, there has been another
study showing that ANXA1 is expressed on late apoptotic cells but
does not facilitate clearance by macrophages [14]. Annexin A4
(ANXA4), another member of the annexin family, is reported to show
a change in subcellular localization from the nucleus to the cytoplasm
during apoptosis [15], although it is not known whether or not
ANXA4 is expressed on apoptotic cells. Moreover, the roles of ANXA1
and ANXA4 in a pro-inﬂammatory response during coculturing of mac-
rophages with apoptotic cells remain largely unexplored except for one
study in which the effect of phagocytosis of late apoptotic cells on
LPS-induced production of inﬂammatory cytokines was examined [14].
In this study, we therefore examine whether or not ANXA1 and
ANXA4 are expressed on the surface of apoptotic cells, and whether
or not ANXA1 and ANXA4 suppress MIP-2 or IL-8 production during
coculturing of macrophages with apoptotic cells.
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2.1. Preparation of human ANXA1 and ANXA4
The glutathione-S-transferase (GST) fusion protein expression
vectors, pGEX-6P-1-human ANXA1 and pGEX-6P-1-human ANXA4,
were provided by Dr. Isamu Matsumoto of Ochanomizu University.
Each vector was introduced into E. coli JM109 cells. The transformed
cells were cultivated in 500 ml of LB broth (Invitrogen) containing
50 μg/ml of ampicillin. When the absorbance of the cell culture at
600 nm reached approximately 1.0, expression was induced by the
addition of 1 mM isopropyl-ß-D-thiogalactopyranoside. The cells were
cultured overnight at 37 °C with constant shaking, and then harvested
as a pellet by centrifugation. The pellet was resuspended in PBS contain-
ing 2 mMEDTA, 0.1 mMdithiothreitol (DTT), 1 μg/ml aprotinin, 1 μg/ml
α-anti trypsin, 0.01 μg/ml soybean trypsin inhibitor, 1 μg/ml leupeptin
and 1 μg/ml pepstatin A. After Triton X-100 had been added to 0.75%,
the cells were solubilized by freezing–thawing (twice) and sonication
(ten times). After centrifugal separation, the supernatant was collected
as the soluble fraction and mixed with Sepharose 4B beads (GE Health-
care), which had been equilibrated with PBS. This mixture was rotated
for 6 h at 4 °C, followed by centrifugation. The supernatant was then
mixed with glutathione-Sepharose 4B beads (GE Healthcare), which
had been equilibrated with PBS. This mixture was rotated at 4 °C
overnight. The beads were then washed with PBS ﬁve times, andrANXA4
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Fig. 1. Characterization of anti-human ANXA1 and anti-human ANXA4 antibodies. (A) Recom
byWestern blotting with anti-human ANXA1 and anti-human ANXA4 antibodies. Boxes show
ably represent fragments of human ANXA1. (B, C) HeLa cells, at a cell density of 2×105 cel
culturing for 4 or 12 h and preparation of cell lysates with a lysis buffer containing 20 mM
cells were subjected to SDS PAGE, followed by Western blotting with anti-human ANXA
ANXA1 and ANXA4 at 100 ng/ml were added to a 96 well microplate, followed by addition o
concentration was 1.3 mg/ml. Then HRP-conjugated goat anti-rabbit IgG was added to eachresuspended in 50 mM Tris–HCl (pH 7.0) containing 150 mM NaCl,
1 mM EDTA and 1 mM DTT (cleavage buffer). This suspension was
then loaded onto a Poly-Prep chromatography column (Bio-Rad),
followed by the addition of the cleavage buffer containing PreScission
protease and incubation for 4 h at 4 °C. After centrifugal separation,
the supernatant was collected and dialyzed against PBS.
2.2. Immunization and preparation of antibodies
JapaneseWhite rabbits, which had been purchased from Sankyo Lab
Service (Tokyo), were immunizedwith 500 μg aliquots of antigen prep-
arations in Freund's complete adjuvant (Difco). Fourweeks later, boost-
er immunizations were performed with 500 μg of antigen in Freund's
incomplete adjuvant (Difco) every two weeks. Whole blood was
obtained and then subjected to incubation at 37 °C for 1 h and at 4 °C
overnight, followed by centrifugation. Serum was mixed with an
equal volume of 60 mM sodium acetate buffer (pH 4.0) and a 0.04
volume of octanoic acid, followed by stirring for 30 min at r.t. and
centrifugation. The supernatantwas then precipitatedwith ammonium
sulfate.
2.3. Western blotting analysis
The recombinant antigen proteins and HeLa cell lysates were
subjected to 0.1% SDS–12.5% polyacrylamide gel electrophoresis and31
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Fig. 2. Surface expression of PS, ANXA1 and ANXA4 during culturing of UV-irradiated
HeLa cells. HeLa cells, at a cell density of 2×105 cells/ml, were irradiated with UV at
230 mW/cm2 (total dose of 50 mJ/cm2), followed by culturing. Surface expression of
PS (A), ANXA1 and ANXA4 (B) was analyzed with a ﬂow cytometer according to the
methods described under Materials and Methods. The results in (A) are expressed as
the percentages of early (PS+, PI−) or late (PI+) apoptotic cells, and all the results
are expressed as means±standard error. n=3–6.
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ence). The membranes were treated with a 2% skim milk solution.
After washing of the membranes with 0.05% Tween-PBS, the antigens
were detected with rabbit anti-human ANXA1 or ANXA4 antibodies,
HRP-conjugated goat anti-rabbit IgG (Invitrogen), and ECL Western
blotting detection reagents (Amersham Bioscience).
2.4. Induction of apoptosis
HeLa cells were seeded onto a plastic dish at a cell density of
5×104 cells/ml, and then incubated overnight. After washing with PBS
three times, the cells were irradiated with UV at a dose of 230mW/cm2
for 217 s (50 mJ/cm2). The cells were then incubated at 37 °C for various
times.
Human peripheral blood neutrophils were isolated from heparinized
venous blood from volunteers with informed consent according to the
standardmethod. Brieﬂy, peripheral bloodwasmixedwith Dextran solu-
tion at a ﬁnal concentration of 1%, followed by centrifugation and hemo-
lysis. The cells were then subjected to Ficoll density gradient. The cells
were suspended in RPMI1640medium containing 7% FCS at a cell density
of 5×105 cells/ml, and then incubated at 37 °C for various times.
2.5. Flow cytometric analysis
The HeLa cells or human neutrophils were centrifuged, and the cell
pellet was incubatedwith FITC-labeled annexin V and propidium iodide
(PI) for 5 min at r.t. After washingwith PBS, the cells were suspended ina sheath solution (Iso Flow) (Beckman Coulter) and ﬁltered through a
mesh, followed by ﬂow cytometric analysis with FACSCalibur.
The HeLa cells or human neutrophils were centrifuged and the cell
pellet was incubated with human Fc receptor blocking reagent (Clear
Back) (MBL, Nagoya) for 5 min at r.t. The cells were then incubated
with 0.5 μg anti-human ANXA1 antibodies, anti-human ANXA4 anti-
bodies, or control normal IgG (TOYOBO) for 30 min on ice, followed
by washing with PBS containing 0.5% BSA and 0.01% NaN3 (staining
buffer) twice and further incubation with 0.5 μg biotinylated goat
anti-rabbit IgG F(ab′)2 fragment (American Qualex). The cells were
then washed, and incubated with streptavidin-PE for 30 min on ice.
After washing with the staining buffer, the cells were suspended in
the sheath solution (Iso Flow) and ﬁltered through a mesh, followed
by ﬂow cytometric analysis with FACSCalibur.
2.6. Coculturing of mouse peritoneal macrophages or human macro-
phages with apoptotic cells
Mouse peritoneal cells were obtained from CDF1 mice (Sankyo Lab
Service) by peritoneal lavage, and then centrifuged. The cells were
then suspended in RPMI1640 medium containing 7% FCS, allowed to
adhere to each well of a 96 well plate at 2×105 cells/well, incubated
for 3 h at 37 °C, and washed with PBS three times. Approximately half
of the cells were obtained as macrophages, as judged on staining with
a FITC-labeled anti-F4/80 monoclonal antibody.
Human macrophages were obtained from peripheral blood mono-
cytes according to the method [16] by using recombinant human
M-CSF (PeproTech, USA) instead of human urine-derived M-CSF.
Apoptotic HeLa cells or human neutrophils were then added to
mouse peritoneal macrophages or human macrophages in the ratio of
1:1, followed by incubation for 24 h at 37 °C. The supernatants were
then harvested, and stored at−30 °C until assaying. The MIP-2 or IL-8
levels in the supernatantswere determinedwith speciﬁc ELISAs (Pepro-
Tech, USA).
2.7. Confocal microscopy
Apoptotic HeLa cells were ﬁxed with neutral buffered 2% formalde-
hyde (Nakarai, Kyoto) for 20 min at r.t. The cellswere thenwashedwith
the staining buffer, followed by permeabilization with PBS containing
0.2% digitonin, 0.5% BSA and 0.01% NaN3 for 5 min on ice and washing
with the staining buffer twice. The cells were then stained with anti-
human ANXA1 or ANXA4 antibodies and further incubated with
biotinylated goat anti-rabbit IgG F(ab′)2 fragment. The cells were then
incubated with streptavidin-FITC for 30 min on ice, and cytospun onto
a slide glass, followed by examination under a confocal microscope
(FluoView FV1000) (Olympus, Tokyo).
3. Results
3.1. Surface expression of PS, ANXA1 and ANXA4 during culturing of
UV-irradiated HeLa cells
We prepared recombinant human ANXA1 and ANXA4 to raise anti-
bodies against these proteins in rabbits. We then characterized the an-
tibodies as shown in Fig. 1. Each antibodywas speciﬁc to human ANXA1
or ANXA4, respectively, as demonstrated with recombinant human
ANXA1 and ANXA4 as well as HeLa cell lysates (Fig. 1A, B and C). More-
over, these antibodies possessed fairly high titers to each antigen
(Fig. 1D).
We then examined cell surface expression of PS, ANXA1 and ANXA4
on apoptotic HeLa cells by ﬂow cytometry according to the methods
described under Materials and methods (Fig. 2). For this purpose,
apoptotic HeLa cells were obtained by UV irradiation and subsequent
incubation for various times. As shown in Fig. 2A, PS was transiently
expressed, the peak being at 8 h. In contrast, ANXA1 and, to a lesser
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Fig. 3. A change in the subcellular localization of ANXA1 during culturing of UV-irradiated HeLa cells. (A) Either untreated HeLa cells (non-apo) or HeLa cells cultured for 16 h after
UV exposure (UV-apo 16 h) were permeabilized with 0.2% digitonin, followed by staining with anti-human ANXA1 antibodies. The nuclei were stained with 300 nM DAPI in PBS for
5 min. The cells were then examined under a confocal microscope. Triangles showed translocation of ANXA1 from nuclei. Original magniﬁcation: ×400. (B) The percentage of the
HeLa cells without intranuclear ANXA1 was determined in randomly chosen four different ﬁelds, and the results are expressed as means±standard error. n=2. (C) Either
untreated HeLa cells or ones cultured for 16 h after UV exposure (1.5×106 cells) were separated into the nuclear and cytoplasmic fractions according to the method in the reference
[27], followed by SDS PAGE and Western blotting. 1 untreated HeLa nuclei, 2 untreated HeLa cytoplasm, 3 apoptotic HeLa nuclei, and 4 apoptotic HeLa cytoplasm.
207T. Iwasa et al. / Biochimica et Biophysica Acta 1822 (2012) 204–211extent, ANXA4 were expressed at 16 and 24 h when the cells were
positive for PI (Fig. 2B), indicating that the cell surface expression of
ANXA1 and ANXA4 is associated with late apoptotic HeLa cells.
We also determined the change in the subcellular localization of
ANXA1 and ANXA4 under a confocal microscope. ANXA1 was
detected throughout untreated HeLa cells (Fig. 3A, upper panels). In
contrast, in late apoptotic HeLa cells, ANXA1 appears to be translo-
cated from the nucleus to the cytoplasm (Fig. 3A, lower panels). The
percentage of the cells without intranuclear ANXA1 in apoptotic
HeLa cells was over 50%, being much higher than that in untreated
HeLa cells (Fig. 3B). We conﬁrmed the change in the subcellularlocalization of ANXA1 by Western blotting after separation into the
nuclear and cytoplasmic fractions (Fig. 3C, see Discussion). ANXA4
was hardly detected under the confocal microscope even in untreated
HeLa cells (data not shown).
ANXA1 and ANXA4 were expressed on the surface of late apoptotic
HeLa cells minimally positive for PS, suggesting that ANXA1 and
ANXA4 bind to molecule(s) other than PS. Because annexins bind to
PS in a calcium-dependent manner, there is a possibility that the cell
surface expression of ANXA1 and ANXA4 is not dependent on calcium.
We therefore examined the effect of EGTA treatment. To our surprise,
EGTA treatment signiﬁcantly decreased the cell surface expression of
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Fig. 4. Decrease in cell surface ANXA1 and ANXA4 caused by EGTA. HeLa cells cultured
for 16 h after UV exposure were washed with buffer in the presence or absence of
10 mM EGTA, followed by staining with anti-human ANXA1 (A) or anti-human
ANXA4 (B) antibodies in the presence or absence of 10 mM EGTA and analysis with a
ﬂow cytometer. The results were expressed as means±standard error. n=3,
* Pb0.05 as compared with EGTA.
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Fig. 5. Surface expression of PS, ANXA1 and ANXA4 during culturing of human peripheral
blood neutrophils. Human peripheral blood neutrophils, at a cell density of 5×105 cells/
ml, were cultured for various times. Surface expression of PS (A), ANXA1 and ANXA4
(B) was then analyzed with a ﬂow cytometer according to the methods described under
Materials and methods. The results in (A) are expressed as the percentages of early
(PS+, PI−) or late (PI+) apoptotic cells, and all the results are expressed as means±
standard error. n=3–6.
208 T. Iwasa et al. / Biochimica et Biophysica Acta 1822 (2012) 204–211ANXA1 and ANXA4 (Fig. 4), suggesting that ANXA1 and ANXA4 bind to
molecule(s) other than PS in a calcium-dependent manner.
3.2. Surface expression of PS, ANXA1 and ANXA4 during culturing of human
neutrophils
We then obtained second apoptotic cells by culturing human neutro-
phils, and examined the cell surface expression of PS, ANXA1 and ANXA4
by ﬂow cytometry. PS was transiently expressed, the peak being at 4 h
(Fig. 5A). The cell surface expression of ANXA1 was detected at 4 h and
then gradually increased (Fig. 5B). Therefore, unlike in the case of HeLa
cells, the cell surface expression of ANXA1 on apoptotic human neutro-
phils was associatedwith not only early apoptosis but also late apoptosis.
Only a small amount of ANXA4 was detected at all times.
3.3. Effect of anti-human ANXA1 or ANXA4 antibodies onMIP-2 production
on coculturing of mouse macrophages with apoptotic human neutrophils
We previously reported that IL-8 or MIP-2 is produced on cocultur-
ing of human or mouse macrophages with late apoptotic cells, such as
IL-2-dependent CTLL-2 cells, P388 cells and human neutrophils
[2,3,16]. We therefore examined whether or not late apoptotic HeLa
cells and human neutrophils induced MIP-2 production after cocultur-
ingwithmouseperitonealmacrophages. Late apoptotic HeLa cells hard-
ly induced MIP-2 production (data not shown), whereas late apoptotic
human neutrophils induced MIP-2 production (Fig. 6). It is not surpris-
ing that late apoptotic HeLa cells did not induce MIP-2 production,because we previously reported that late apoptotic thymocytes induce
a much smaller amount of MIP-2 than late apoptotic CTLL-2 cells and
P388 cells did [17].
We then examined whether or not anti-human ANXA1 or ANXA4
antibodies affect MIP-2 production by coculturing mouse macrophages
with early or late apoptotic human neutrophils in the absence or pres-
ence of IFN-γ, because our recent study demonstrated that IFN-γmod-
ulates cytokine production of mousemacrophages in response to either
early apoptotic mouse neutrophils or late apoptotic ones [18]. In the
absence of IFN-γ, both anti-human ANXA1 antibodies and anti-human
ANXA4 antibodies increased MIP-2 production in response to late
apoptotic human neutrophils but not early apoptotic ones signiﬁcantly,
as comparedwith control antibodies (Fig. 6A). In the presence of IFN-γ,
however, both antibodies increased MIP-2 production in response to
not only late apoptotic human neutrophils but also early apoptotic
ones (Fig. 6B).
3.4. Cross-reactivity of anti-human ANXA1 antibodies to mouse ANXA1
Although our rabbit anti-human ANXA1 antibodies were obtained
by immunization with human ANXA1, there is a possibility that anti-
human ANXA1 antibodies cross-react with mouse ANXA1. Unstimu-
lated mouse macrophages were negative for staining by anti-human
ANXA1 antibodies, whereas IFN-γ-stimulated ones were positive
(Fig. 7, top vs. middle), suggesting that our preparation of anti-human
ANXA1 antibodies cross-reacts withmouse ANXA1.Moreover, late apo-
ptotic neutrophils-fed macrophages were also positive for staining by
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Fig. 6. Effect of anti-human ANXA1 or anti-human ANXA4 antibodies on MIP-2 production on coculturing of mouse macrophages with apoptotic human peripheral blood neutro-
phils. Human peripheral blood neutrophils were cultured for 4 or 24 h, followed by the addition of 10 or 50 μg/ml of anti-human ANXA1 antibodies, anti-human ANXA4 antibodies
or normal rabbit IgG. After incubation on ice for 30 min, the apoptotic human neutrophils were added to the mouse peritoneal macrophages in the ratio of 1 to 1 in the absence
(A) or presence (B) of 100 ng/ml IFN-γ. Culture supernatants were then harvested, followed by analysis by MIP-2 ELISA. Three independent experiments were carried out and
the results are expressed as means±standard error. * Pb0.05.
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phages were washed several times to remove free and bound apoptotic
neutrophils, it is likely that the signalswere derived frommousemacro-
phages but not human neutrophils.
3.5. Effect of anti-human ANXA1 or ANXA4 antibodies on IL-8 production
on coculturing of human macrophages with apoptotic human neutrophils
We also examinedwhether or not late apoptotic human neutrophils
induced IL-8 production after coculturing with human macrophages.
Late apoptotic human neutrophils induced IL-8 production (Fig. 8).
We then examined whether or not anti-human ANXA1 or ANXA4 anti-
bodies affect IL-8 production by coculturing human macrophages with
late apoptotic human neutrophils. Both anti-human ANXA1 antibodies
and anti-human ANXA4 antibodies increased IL-8 production in
response to late apoptotic human neutrophils signiﬁcantly, as com-
pared with control antibodies (Fig. 8).
4. Discussion
It has been reported that ANXA1 is expressed on either early [9,10]
or late apoptotic cells [14]. In this study, ANXA1 and, to a lesser extent,
ANXA4were detected on the surface of late apoptotic HeLa cells, where-
as ANXA1 and a small amount of ANXA4were detected on the surface of
both early and late apoptotic human neutrophils. These results suggest
that the stage of apoptosis when ANXA1 and ANXA4 are expressed on
the cell surface depends on the cell type, although the underlyingmech-
anism is currently unknown. The reasonwhy the level of surfaceANXA4was much smaller than that of ANXA1 in HeLa cells may be related to
that, as compared with ANXA1, a smaller amount of ANXA4 was
detected in untreated HeLa cells (Fig. 1B). ANXA1 was found to change
in subcellular localization from the nucleus to the cytoplasm in late ap-
optotic HeLa cells, as evidenced by staining with both anti-human
ANXA1 antibodies and DAPI (Fig. 3A). Of note is that the total level of
ANXA1 in apoptotic HeLa cells is smaller than that in untreated HeLa
cells (Figs. 1B and 3C), raising the alternative possibility that ANXA1
in the nuclear region is decreased below the detection limit. Although
it is not known how ANXA1 is expressed on the cell surface, identiﬁca-
tion of the cell surface molecule(s) to which ANXA1 binds in a calcium-
dependentmannermay provide a clue as to the underlyingmechanism.
Calcium binding to ANXA1 causes protein re-organization, with expo-
sure of the N-terminus [19], which may be required for binding to the
receptor.
Although ANXA1 is known as an anti-inﬂammatory protein, its role
in the inﬂammatory response during coculturing of macrophages with
apoptotic cells remains largely unexplored. In this study, we found
that, in the absence of IFN-γ, anti-human ANXA1 antibodies and, to a
lesser extent, anti-human ANXA4 ones increased MIP-2 production
during coculturing of macrophages with late apoptotic human neutro-
phils, but not early apoptotic ones. The combination of these two anti-
bodies may further increase MIP-2 production, although we did not
examine it. The exact reason why anti-human ANXA1 antibodies are
more effective than anti-human ANXA4 ones is not known at present,
although it may be related to the difference in the levels of cell surface
ANXA1 and ANXA4. Moreover, the anti-inﬂammatory activities of
ANXA1 and ANXA4 may suggest the role of the core domain conserved
Fig. 7. Cross-reactivity of anti-human ANXA1 antibodies with mouse ANXA1. Mouse peritoneal macrophages were cultured for 3 h in the absence or presence of 100 ng/ml IFN-γ.
Alternatively, mouse peritoneal macrophages were fed for 3 h with human peripheral blood neutrophils cultured for 24 h and stained with PKH26-Red, followed by extensive
washing to remove free or attached apoptotic human neutrophils. The macrophages were then ﬁxed with 2% formaldehyde, followed by staining with anti-human ANXA1
antibodies without permeabilization and examination under a confocal microscope. Original magniﬁcation, ×400. Green: ANXA1, Red: apoptotic cells.
210 T. Iwasa et al. / Biochimica et Biophysica Acta 1822 (2012) 204–211in ANXA1 and ANXA4, although this contrasts with the notion that the
N terminal domain is responsible for the anti-inﬂammatory function of
ANXA1 [13]. Alternatively, the anti-inﬂammatory activities of ANXA1
and ANXA4 may be different from each other. If the latter possibility is
correct, there is the possibility that FPR2 is responsible for ANXA1-
mediated suppression of MIP-2 production, because ANXA1 activatesFig. 8. Effect of anti-human ANXA1 or anti-human ANXA4 antibodies on IL-8 production
on coculturing of human macrophages with apoptotic human peripheral blood neutro-
phils. Human peripheral blood neutrophils were cultured for 24 h, followed by the addi-
tion of 10 or 50 μg/ml of anti-human ANXA1 antibodies, anti-human ANXA4 antibodies
or normal rabbit IgG. After incubation on ice for 30 min, the apoptotic human neutrophils
were added to the human macrophages in the ratio of 1 to 1. Culture supernatants were
then harvested, followed by analysis by IL-8 ELISA. Three independent experiments
were carried out and the results are expressed as means±standard error. * Pb0.05,
** Pb0.01, ***Pb0.001.FPR2 to promote phagocytosis [20]. Under the conditionwe used, how-
ever, anti-ANXA1 antibodies did not suppress phagocytosis, suggesting
that as yet unknown receptor other than FPR2 may be involved in
ANXA1-mediated suppression (data not shown). In agreement with
this, a previous study reported that ANXA1 regulates macrophage cyto-
kine production via “glucocorticoid-induced leucine zipper” protein
and that it does not require ANXA1 binding to FPR family members
[21]. In this study, we also found that, in the presence of IFN-γ, both an-
tibodies increased MIP-2 production during coculturing of macro-
phages with not only late apoptotic human neutrophils but also early
apoptotic ones. It is not known at present, however, why the effect on
MIP-2 production in response to early apoptotic human neutrophils in
the presence of IFN-γ differs from that in the absence of IFN-γ. The dif-
ference may be due to either enhanced production of ANXA1 in IFN-γ-
stimulated macrophages (Fig. 7) or modulation of cytokine production
by IFN-γ [18].
Both anti-human ANXA1 antibodies and anti-human ANXA4 ones
increased IL-8 production during coculturing of macrophages with
late apoptotic human neutrophils. This further supports the anti-
inﬂammatory role of ANXA1 and ANXA4 upon an encounter of macro-
phages to late apoptotic neutrophils.
What mechanism is responsible for the suppressive effect of ANXA1
onMIP-2 production in response to late apoptotic cells? Recently it was
reported that LPS-induced cytokine expression was increased in
ANXA1−/−macrophages, and that it was accompanied by signiﬁcantly
increased LPS-induced activation of ERK and JNKMAPK [21]. In contrast,
exogenous ANXA1 reportedly activates ERK in another study [22]. Al-
though it is difﬁcult to reconcile these results, the former result [21] is
consistent with our previous report that ERK activation is critical in
the MIP-2 production by macrophages in response to late apoptotic
211T. Iwasa et al. / Biochimica et Biophysica Acta 1822 (2012) 204–211cells [23], raising the possibility that ERK activation is suppressed by
ANXA1, thereby leading to a decrease in MIP-2 production.
TGF-β is responsible for the suppressive effect of early apoptotic
cells on the inﬂammatory response of macrophages in response to LPS
and zymosan, although TGF-β is produced bymacrophages in response
to both early and late apoptotic cells [24,25]. It is not known, however,
whether or not TGF-β suppresses the response of macrophages to early
apoptotic cells. In contrast, ANXA1 and ANXA4 suppress the inﬂamma-
tory response of mouse macrophages to not only late apoptotic human
neutrophils but also early apoptotic ones in the presence of IFN-γ.
In this study we did not examine whether or not cell-to-cell contact
is required for MIP-2 production. Since our previous study demonstrat-
ed that culture supernatant of late apoptoticmouse neutrophils induced
TNF-α production by IFN-γ-stimulatedmacrophages but not untreated
ones [18], it is likely thatMIP-2 production in response to late apoptotic
neutrophils in the absence of IFN-γ is dependent on cell-to-cell contact.
We found that our preparation of rabbit anti-human ANXA1 anti-
bodies cross-reacts with ANXA1 on the surface of activatedmousemac-
rophages. Other researchers have also reported the cell surface
expression of ANXA1 on activatedmacrophages that had been obtained
after injection of thioglycollate broth [11], and up-regulation of ANXA1
in activated microglia in Alzheimer's disease [26]. It is thus suggested
that ANXA1 and, presumably, ANXA4 on the surface of both late apo-
ptotic human neutrophils and activated mouse macrophages are in-
volved in the suppression of MIP-2 production.
Overall, our study suggests that ANXA1 and ANXA4 down-regulate
the inﬂammatory response when late apoptotic neutrophils are gener-
ated upon chemotherapy and X-irradiation without an infection.References
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